{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:49:09Z","timestamp":1790916549738,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["14\/25\/02"],"award-info":[{"award-number":["14\/25\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40273-017-0488-2","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T02:49:16Z","timestamp":1486435756000},"page":"805-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-2332","authenticated-orcid":false,"given":"Paul","family":"Tappenden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rawdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kaltenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ghazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"key":"488_CR1","unstructured":"National Institute for Health and Care Excellence. Guide to the processes of technology appraisal. London: NICE; 2014. \n                        https:\/\/www.nice.org.uk\/process\/pmg19\/chapter\/acknowledgements\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR2","unstructured":"Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M. Adalimumab for treating moderate to severe hidradenitis suppurativa: a single technology appraisal. Sheffield: University of Sheffield; 2015. \n                        https:\/\/www.nice.org.uk\/guidance\/TA392\/documents\/committee-papers\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR3","unstructured":"Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M. Adalimumab for treating moderate to severe hidradenitis suppurativa: a single technology appraisal. Addendum: Patient access scheme. Sheffield: University of Sheffield; 2016. \n                        https:\/\/www.nice.org.uk\/guidance\/TA392\/documents\/committee-papers\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR4","unstructured":"Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M. Adalimumab for treating moderate to severe hidradenitis suppurativa: a single technology appraisal. Addendum: ERG critique of company\u2019s ACD response. University of Sheffield, Sheffield. 2016. \n                        https:\/\/www.nice.org.uk\/guidance\/TA392\/documents\/committee-papers-2\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR5","unstructured":"National Institute for Health and Care Excellence. Technology appraisal guidance: adalimumab for treating moderate to severe hidradenitis suppurativa. London: NICE; 2016. \n                        https:\/\/www.nice.org.uk\/guidance\/TA392\n                        \n                    . Accessed 10 Nov 2016."},{"issue":"4","key":"488_CR6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1365-2133.2001.04137.x","volume":"144","author":"JM Werth Von Der","year":"2001","unstructured":"Von Der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809\u201313.","journal-title":"Br J Dermatol"},{"issue":"5","key":"488_CR7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1468-3083.2000.00087.x","volume":"14","author":"JM Werth von der","year":"2000","unstructured":"von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14(5):389\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"488_CR8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","volume":"23","author":"J Revuz","year":"2009","unstructured":"Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23:985\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"488_CR9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"G Jemec","year":"2012","unstructured":"Jemec G. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158\u201364.","journal-title":"N Engl J Med"},{"issue":"90","key":"488_CR10","first-page":"216","volume":"2014","author":"D Dufour","year":"1062","unstructured":"Dufour D, Emtestam L, Jemec G. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 1062;2014(90):216\u201321.","journal-title":"Postgrad Med J"},{"issue":"4","key":"488_CR11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"C Zouboulis","year":"2015","unstructured":"Zouboulis C, Desai N, Emtestam L. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"488_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjd.12104","volume":"168","author":"J Blok","year":"2013","unstructured":"Blok J, van Hattem S, Jonkman M, Horv\u00e1th B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168(2):243\u201352.","journal-title":"Br J Dermatol"},{"issue":"4","key":"488_CR13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/bjd.13866","volume":"173","author":"J Ingram","year":"2015","unstructured":"Ingram J, McPhee M. Management of hidradenitis suppurativa: a UK survey of current practice. Br J Dermatol. 2015;173(4):1070\u20132.","journal-title":"Br J Dermatol"},{"key":"488_CR14","unstructured":"National Institute for Health and Care Excellence. Adalimumab for treating moderate to severe hidradenitis suppurativa\u2014final scope. London: NICE; 2015. \n                        https:\/\/www.nice.org.uk\/guidance\/ta392\/history\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR15","unstructured":"AbbVie Ltd. Adalimumab for treating moderate to severe hidradenitis suppurativa. ID812. Company evidence submission to the National Institute for Health and Care Excellence. London: NICE; 2015. \n                        https:\/\/www.nice.org.uk\/guidance\/TA392\/documents\/final-scope\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR16","unstructured":"AbbVie Ltd. Adalimumab for treating moderate to severe hidradenitis suppurativa. ID812. Response to ERG\u2019s clarification questions. Berkshire: AbbVie; 2015. \n                        https:\/\/www.nice.org.uk\/guidance\/TA392\/documents\/committee-papers\n                        \n                    . Accessed 10 Nov 2016."},{"issue":"6","key":"488_CR17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","volume":"171","author":"A Kimball","year":"2014","unstructured":"Kimball A, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434\u201342.","journal-title":"Br J Dermatol"},{"key":"488_CR18","volume-title":"A phase 3 multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa\u2014PIONEER I. Clinical study report (interim), adalimumab\/protocol","author":"AbbVie Ltd","year":"2015","unstructured":"AbbVie Ltd. A phase 3 multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa\u2014PIONEER I. Clinical study report (interim), adalimumab\/protocol. North Chicago: AbbVie; 2015."},{"key":"488_CR19","unstructured":"AbbVie Ltd. A phase 3 multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa\u2014PIONEER II (Clinical study report (interim), adalimumab\/protocol M11-810). North Chicago: AbbVie; 2015."},{"key":"488_CR20","unstructured":"AbbVie Ltd. Phase 3 open-label study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa\u2014PIONEER (open-label extension). Clinical study report (interim), adalimumab\/protocol M12-555. North Chicago: AbbVie; 2015."},{"issue":"6","key":"488_CR21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bjd.13396","volume":"171","author":"JR Ingram","year":"2014","unstructured":"Ingram JR. Hidradenitis suppurativa outcome measures and treatment goals. Br J Dermatol. 2014;171(6):1293\u20134.","journal-title":"Br J Dermatol"},{"key":"488_CR22","unstructured":"Higgins J, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. \n                        http:\/\/training.cochrane.org\/handbook\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR23","unstructured":"Critical Appraisal Skills Programme (CASP). Cohort study checklist. Oxford: Better Value Healthcare Ltd; 2013. \n                        http:\/\/www.casp-uk.net\/casp-tools-checklists\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR24","unstructured":"BMJ Group, RCPCH Publications Ltd and The Royal Pharmaceutical Society of Great Britain. British national formulary (BNF). 2015. \n                        https:\/\/www.medicinescomplete.com\/mc\/bnf\/current\/\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR25","volume-title":"Costs of health and social care 2014","author":"L Curtis","year":"2014","unstructured":"Curtis L. Costs of health and social care 2014. Kent: University of Kent; 2014."},{"key":"488_CR26","unstructured":"UK Department of Health. NHS reference costs 2013\/14. 2014. \n                        https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2013-to-2014\n                        \n                    . Accessed 10 Nov 2016."},{"key":"488_CR27","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination: adalimumab for treating moderate to severe hidradenitis suppurativa. London: NICE; 2016. \n                        https:\/\/www.nice.org.uk\/guidance\/ta392\/history\n                        \n                    . Accessed 10 Nov 2016."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0488-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T11:06:57Z","timestamp":1502190417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0488-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0488-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]}}}